首页> 美国卫生研究院文献>Therapeutic Advances in Gastroenterology >Fecal microbiota transplantation in relapsing Clostridium difficile infection
【2h】

Fecal microbiota transplantation in relapsing Clostridium difficile infection

机译:粪微生物菌群移植在难治性梭状芽胞杆菌感染中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clostridium difficile infection rates are Climbing in frequency and severity, and the spectrum of susceptible patients is expanding beyond the traditional scope of hospitalized patients receiving antibiotics. Fecal microbiota transplantation is becoming increasingly accepted as an effective and safe intervention in patients with recurrent disease, likely due to the restoration of a disrupted microbiome. Cure rates of > 90% are being consistently reported from multiple centers. Transplantation can be provided through a variety of methodologies, either to the lower proximal, lower distal, or upper gastrointestinal tract. This review summarizes reported results, factors in donor selection, appropriate patient criteria, and the various preparations and mechanisms of fecal microbiota transplant delivery available to clinicians and patients.
机译:艰难梭菌感染的频率和严重性正在上升,易感患者的范围​​正在扩大,超出了接受抗生素治疗的住院患者的传统范围。粪便菌群移植已被越来越多地接受为复发性疾病患者的一种有效且安全的干预措施,这可能是由于微生物组的恢复所致。多个中心一致报告治愈率> 90%。可以通过多种方法向下近端,下远端或上消化道提供移植。这篇综述总结了报告的结果,供体选择的因素,适当的患者标准以及可供临床医生和患者使用的粪便微生物群移植的各种制剂和机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号